Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. covers the month of August 2018, with the report dated August 13, 2018. The filing primarily serves to disclose an Underwriting Agreement dated August 9, 2018, between the Company and Ladenburg Thalmann & Co. Inc., along with associated legal opinions and consents.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a corporate transaction (underwriting agreement) rather than a financial results report.
Material Changes
The material change disclosed is the execution of an Underwriting Agreement with Ladenburg Thalmann & Co. Inc. on August 9, 2018. The filing incorporates legal opinions from Gross, Kleinhendler, Hodak, Halevy, Greenberg, Shenhav & Co. and Haynes and Boone, LLP regarding this transaction.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or specific risk factors related to operations. It includes a standard disclaimer stating that the Form 6-K does not constitute an offer to sell securities and that no sale will occur in jurisdictions where such an offer would be unlawful prior to registration.
Investor Verification Checklist
- Verify the specific terms of the Underwriting Agreement with Ladenburg Thalmann & Co. Inc. referenced in Exhibit 1.1.
- Confirm the status of the Company's Registration Statements on Form S-8 and Form F-3 into which this filing is incorporated.
- Review the legal opinions in Exhibits 5.1 and 5.2 for any conditions precedent to the underwriting.
- Note that no financial performance data is included in this specific filing.